Cercar
01/12/2021
Efficacy of Dupilumab in Atopic Dermatitis: The Patient's Perspective
de Bruin-Weller, M, Merola, JF, Hong, CH, Baldrich, ES, Ettler, K, Sierka, D, Delevry, D, Chen, Z, Rossi, AB. Efficacy of Dupilumab in Atopic Dermatitis: The Patient's Perspective. Dermatology and Therapy. 2021; 11(6)DOI:10.1007/s13555-021-00621-w. PMID:34767181. IF:3.661(Q2/3D).
01/12/2021
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up
Papp, KA, Lebwohl, MG, Puig, L, Ohtsuki, M, Beissert, S, Zeng, J, Rubant, S, Sinvhal, R, Zhao, Y, Soliman, AM, Alperovich, G, Leonardi, C. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. BRITISH JOURNAL OF DERMATOLOGY. 2021; 185(6)DOI:10.1111/bjd.20595. PMID:34157132. IF:11.113(Q1/1D).
01/11/2021
Diagnostic Value of Cutaneous Ultrasound in Verrucous Venous Malformation
Amat-Samaranch, V, Morales-Munera, C, Puig, L, Roe, E. Diagnostic Value of Cutaneous Ultrasound in Verrucous Venous Malformation. Actas Dermo-Sifiliograficas. 2021; 112(10)DOI:10.1016/j.ad.2021.07.002. PMID:. IF:(Q/D).
01/11/2021
Authors' reply to Borg and Thoning: "Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study"
Torres, T, Chiricozzi, A, Puig, L. Authors' reply to Borg and Thoning: "Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study". AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2021; 22(6)DOI:10.1007/s40257-021-00640-5. PMID:34705165. IF:6.233(Q1/2D).
01/11/2021
Satisfactory treatment of mucocutaneous lesions in hereditary hemorrhagic telangiectasia patients with dual pulsed dye laser and neodymium: yttrium-aluminum-garnet
Cubiro, X, Garcia-Melendo, C, Morales-Munera, CE, Roe-Crespo, E, Riera-Mestre, A, Mora-Lujan, JM, Iriarte, A, Puig, L, Baselga, E. Satisfactory treatment of mucocutaneous lesions in hereditary hemorrhagic telangiectasia patients with dual pulsed dye laser and neodymium: yttrium-aluminum-garnet. Dermatologic Therapy. 2021; 34(6)DOI:10.1111/dth.15124. PMID:34486206. IF:3.858(Q2/3D).
01/11/2021
Arguments in favour of excluding MDBGN from the European baseline series. In response to "Comment on MDBGN/DBDCB, the European baseline series, and EU legislation"
Mercader-Garcia, P, Pastor-Nieto, MA, Gonzalez-Perez, R, Gimenez-Arnau, AM, Ruiz-Gonzalez, I, Mora-Fernandez, V, Miquel, J, Silvestre-Salvador, JF, Sanz-Sanchez, T, Perez-Feal, P, Sanchez-Perez, J, Heras-Mendaza, F, Serra-Baldrich, E, Hervella-Garces, M, Gatica-Ortega, ME, Garcia-Doval, I, Borrego, L. Arguments in favour of excluding MDBGN from the European baseline series. In response to "Comment on MDBGN/DBDCB, the European baseline series, and EU legislation". CONTACT DERMATITIS. 2021; 85(5)DOI:10.1111/cod.13941. PMID:34268785. IF:6.419(Q1/1D).
01/11/2021
An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies
Blauvelt, A, Ramharter, M, Cohen, AD, Xu, W, Patel, H, Schuster, C, Riedl, E, Puig, L. An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021; 35(11)DOI:10.1111/jdv.17554. PMID:34310771. IF:9.228(Q1/1D).
01/11/2021
Oral submucous fibrosis presenting with histopathological lichenoid changes as predominant feature: Report of five cases and review of the literature
Campos, MC, Tubau, C, Segura, S, Gonzalez-Farre, M, Iglesias-Sancho, M, Fernandez-Figueras, MT, Garcia-Muret, MP, Mozos, A. Oral submucous fibrosis presenting with histopathological lichenoid changes as predominant feature: Report of five cases and review of the literature. JOURNAL OF CUTANEOUS PATHOLOGY. 2021; 48(11)DOI:10.1111/cup.14084. PMID:34151457. IF:1.458(Q4/8D).